Growth hormone (somatotropin) has long been a popular means of gaining weight and making the figure more expressive. It is used not only in medicine, but also in sport, because of its valuable properties. Genotropin 36 IU Pfizer Labs contains a modern analogue of natural growth hormone. Available in a practical pen format, where you can easily select the appropriate dosage and use it as directed.
Positive effects of Genotropin 36 IU Pfizer Labs
Growth hormone has many positive properties, but increasing strength and endurance is not one of them. Consequently, it makes no sense to buy this drug to increase productivity. However, it is very much in demand in bodybuilding, as it gives the following results:
- increase in lean, high-quality muscle mass;
- formation of a beautiful, clear relief
- elimination of excess subcutaneous fat;
- improved joints and stronger bone tissue.
Because bone tissue is strengthened, the risk of damage during physical effort is reduced. Growth hormone has an anabolic effect and retains fluid in muscle cells, due to its ability to increase muscle mass. The drug also increases the amount of insulin-like growth factor required for muscle development. The relief is formed as the subcutaneous fat disappears and the muscles become larger and stand out better.
After using somatotropin, they do not undergo separate drying. It immediately gives the desired effect. Other properties include:
- boosting immunity;
- wound healing;
- regulation of energy exchanges.
Genotropin 36 IU Pfizer Labs is approved for both sexes. It has no oestrogenic or androgenic activity, so it does not cause the side effects that would make it unsuitable for women or men. But there are still some side effects and contraindications.
Possible negative effects
Side effects may occur if:
- too high a dose is selected
- the course has been delayed and it is time to finish;
- there is an individual sensitivity to the active substance.
The main symptoms indicating that you should consult a doctor are:
- pain in the hand, numbness in the fingers;
- excessive accumulation of fluid;
- high blood pressure;
- high blood sugar.
The drug is contraindicated in cases of thyroid gland hypofunction, enlarged organs, the presence of neoplasms, and during pregnancy and breast-feeding. The drug should not be taken until the growth zones in the bones have closed (age 21), so as not to interfere with the process of skeletal growth and development.
How to take it
Somatropin is taken at bedtime. It is administered by injection. Thanks to the practical pen shape of Genotropin 36 IU Pfizer Labs, you do not need to use several tools to make an injection.
The dosage is chosen individually. Factors that affect it: physical indicators, intake targets, experience of using sports medication. For a mass gathering course, a larger quantity of medication will be required than for rescue training.
Frequency of administration: 3 to 4 times a week. Duration of course: several months. This will depend on the sensitivity of the athlete’s body to the active substance and the strength of the result. A medical consultation is necessary to rule out any contraindications.
List of references
- “Growth Hormone Replacement Therapy with Genotropin in Children with Growth Hormone Deficiency: A Long-Term Observational Study” – Cianfarani S et al. (Published in Italian Journal of Pediatrics, 2019)
- “Effect of Genotropin on Adult Height in Turner Syndrome: A Randomized Controlled Trial” – Ross JL et al. (Published in The Journal of the American Medical Association, 2003)
- “Safety and Efficacy of Genotropin in Children with Short Stature: The European Increlex Growth Forum Database Experience” – Carel JC et al. (Published in Hormone Research in Paediatrics, 2018)
- “Growth Hormone Treatment with Genotropin in Children Born Small for Gestational Age: 15-Year Analysis of Long-Term Safety and Efficacy” – Hokken-Koelega AC et al. (Published in European Journal of Endocrinology, 2019)
- “Long-Term Effects of Growth Hormone Therapy with Genotropin in Adults with Growth Hormone Deficiency” – Molitch ME et al. (Published in The Journal of Clinical Endocrinology & Metabolism, 2005)